CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

P. Queirolo, B. Dozin, A. Morabito, B. Banelli, R. Carosio, V. Fontana, P.F. Ferrucci, C. Martinoli, E. Cocorocchio, P.A. Ascierto, G. Madonna, E. Simeone, F. De Galitiis, G.C. Antonini Cappellini, P. Marchetti, M. Guida, S. Tommasi, L. Ghilardi, B. Merelli, P. FavaS. Osella-Abate, M. Guidoboni, M. Romani, D. Ferone, F. Spagnolo, M.P. Pistillo, Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalEuropean journal of cancer
Publication statusPublished - 2018


  • cytotoxic T lymphocyte antigen 4
  • ipilimumab
  • cancer immunotherapy
  • cancer survival
  • endocrine disease
  • genetic model
  • genetic variability
  • genotype
  • human
  • hypophysitis
  • Letter
  • metastatic melanoma
  • priority journal
  • single nucleotide polymorphism
  • thyroiditis

Cite this